A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin [0.03%]
一项关于择林西替尼（一种全厄布酪氨酸激酶抑制剂的低氧激活前药）用于治疗复发性或转移性的头颈部鳞状细胞癌或皮肤癌Ⅱ期研究
Luke S McLean,Tessa A Morris,Ann Gramza et al.
Luke S McLean et al.
Background: Tarloxotinib, a hypoxia-activated prodrug of an irreversible pan-ErbB tyrosine kinase inhibitor, represents a novel therapeutic which exploits the tumor-specific hypoxic environment as a mechanism for tumor-sp...
The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines [0.03%]
β-山柏脑（一种诱导S期细胞周期阻滞的托普酚衍生物）对头颈部鳞状细胞癌系放射增敏作用的影响
Markus Haas,Teresa Lenz,Lorenz Kadletz-Wanke et al.
Markus Haas et al.
Background: Resistance to radiotherapy is a common cause of treatment failure in advanced head and neck squamous cell carcinoma (HNSCC). ß-Thujaplicin, a natural tropolone derivative, acts as an anti-cancer agent and has...
The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis [0.03%]
免疫检查点抑制剂联合化疗治疗晚期非小细胞肺癌患者的疗效和安全性：一项荟萃分析
Li-Fang Meng,Jian-Feng Huang,Peng-Hui Luo et al.
Li-Fang Meng et al.
Objective: To evaluate the efficacy and safety of immune checkpoint inhibitor (ICI) and chemotherapy (CT) versus CT alone in advanced non-small-cell lung cancer (NSCLC). ...
Practical consideration for successful sequential tumor biopsies in first-in-human trials [0.03%]
首次人体试验中成功进行肿瘤连续活检的实际考量
Takafumi Koyama,Toshio Shimizu,Jun Sato et al.
Takafumi Koyama et al.
In first-in-human (FIH) trials, sequential tumor biopsies, i.e., two consecutive tumor biopsies, the first performed at baseline (pretreatment) and the second during the early treatment period (on-treatment), provide proof of concept in inv...
Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas [0.03%]
血管肉瘤中组蛋白去乙酰化酶抑制剂与常规细胞毒性化疗的协同作用
Yingjun Zhang,C H Wong,Herbert H F Loong
Yingjun Zhang
A small molecule inhibitor of VSIG-8 prevents its binding to VISTA [0.03%]
一种VSIG-8的小分子抑制剂可防止其与VISTA结合
Wenting Chen,Chenxin Qie,Xinlei Hu et al.
Wenting Chen et al.
The V-region immunoglobulin-containing suppressor of T cell activation (VISTA), a unique B7 family member, is an attractive immunotherapeutic target for cancer, autoimmune and inflammatory diseases. In 2016, a patent demonstrated V-Set and ...
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers [0.03%]
抗EphA2抗体DS-8895a治疗晚期或转移性EphA2阳性癌症的I期安全性和生物成像试验
Hui K Gan,Sagun Parakh,F T Lee et al.
Hui K Gan et al.
Ephrin type-A 2 (EphA2) is a transmembrane receptor expressed in epithelial cancers. We report on a phase I dose escalation and biodistribution study of DS-8895a, an anti-EphA2 antibody, in patients with advanced EphA2 positive cancers. DS-...
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA [0.03%]
FDA、EMA、加拿大卫生部和TGA批准的新靶向抗癌药物的初始和补充适应证审批
Daniel Tobias Michaeli,Mackenzie Mills,Thomas Michaeli et al.
Daniel Tobias Michaeli et al.
Background: Previous research focused on the clinical evidence supporting new cancer drugs' initial US Food and Drug Administration (FDA) approval. However, targeted drugs are increasingly approved for supplementary indic...
Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy [0.03%]
钯(II)希夫碱配合物在早期阻止细胞周期，诱导凋亡并减少艾氏腹水瘤荷瘤小鼠的肿瘤负荷：一种新的抗肿瘤候选药物
Shahd M Hassona,Entsar A Saad,Hala A Kiwan et al.
Shahd M Hassona et al.
Although many cancer drugs are clinically approved, they still suffer from no adequate efficiency or drug resistance, or bad side effects. Therefore, developing safer alternatives of competitive efficiency is needed. This study aimed to inv...
The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis [0.03%]
免疫调节剂米法莫特丁联合辅助化疗治疗早期间质肉瘤的回顾性分析
Stefania Kokkali,Ioannis Kotsantis,Elpida Magou et al.
Stefania Kokkali et al.
Background: Current treatment recommendations for high grade non-metastatic osteosarcoma include perioperative chemotherapy and surgery. Despite this intensive protocol, approximately 40% of patients will relapse. The add...